Uterine prolapse
Also known as: Uterus, Womb, Myometrium, Uterine
Methodology & AI Transparency ⓘ
Uterine prolapse Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Uterine prolapse (also termed Uterus or Womb) (N81.4) in OB/GYN & PCOS relies on metabolic/thyroid/prolactin hormone panels [Uterine prolapse N81.4], guiding step-wise therapeutic adjustments toward Free & Total in Uterine prolapse (N81.4: Testosterone + SHBG) (Sex-specific physiological range (N81.4)).
- 2 Real-world patient consensus: Clinical coding for Uterine prolapse uses ICD-10 N81.4 across OB/GYN & PCOS specialty care.
- 3 Typical cash cost range: Clinicians assessing Uterine prolapse focus on or benign leiomyoma in Uterine prolapse (N81.4: smooth-muscle proliferation) and targeted history.
- 4 Top reported side effects / signs: Longitudinal Uterine prolapse monitoring tracks LH, FSH & in Uterine prolapse (N81.4: Prolactin) toward Normal ovulatory endocrine axis (N81.4).
Ask our AI Specialists anything about Uterine prolapse
What Is Uterine prolapse?
Clinical triage of Uterine prolapse (also termed Uterus or Womb) (N81.4) in OB/GYN & PCOS relies on metabolic/thyroid/prolactin hormone panels [Uterine prolapse N81.4], guiding step-wise therapeutic adjustments toward Free & Total in Uterine prolapse (N81.4: Testosterone + SHBG) (Sex-specific physiological range (N81.4)).
Pathophysiology, Underlying Causes & Clinical Presentation
In Uterine prolapse (N81.4), physiological disruption stems from or benign leiomyoma in Uterine prolapse (N81.4: smooth-muscle proliferation), informing PCOS, Endometriosis & Gynecologic Health protocols that track Free & Total in Uterine prolapse (N81.4: Testosterone + SHBG) (Sex-specific physiological range (N81.4)).
Common Symptoms & Clinical Signs
- • Presentation of Uterine prolapse (N81.4): pelvic pressure, bloating, in Uterine prolapse (N81.4: or pain radiating)
- • Secondary Uterine prolapse clinical sign: irregular, infrequent, or in Uterine prolapse (N81.4: absent ovulatory menstrual)
- • Symptom flares in Uterine prolapse correlating with LH, FSH & in Uterine prolapse (N81.4: Prolactin) deviation outside Normal ovulatory endocrine axis (N81.4)
- • Functional ob/gyn & pcos impact requiring metabolic/thyroid/prolactin hormone panels [Uterine prolapse N81.4] evaluation (N81.4)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Uterine prolapse Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N81.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | PCOS, Endometriosis & Gynecologic Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: LH, FSH & in Uterine prolapse (N81.4: Prolactin) | Normal ovulatory endocrine axis (N81.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Free & Total in Uterine prolapse (N81.4: Testosterone + SHBG) | Sex-specific physiological range (N81.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Insulin & in Uterine prolapse (N81.4: HbA1c) | Fasting insulin < 8 uIU/mL (N81.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Uterine prolapse
Treatment selection for Uterine prolapse depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Uterine prolapse)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Pain Reduction in Linzagolix-Treated Patients With Uterine Fibroids: A Secondary: What a 1,012-Participant Study Found This analysis showed that reductions in pain were significantly mediated by reductions in HMB (all doses) and FV (200 mg alone) in linzagolix-treated women with UFs. BJOG : an international journal of obstetrics and gynaecology • 2025-08-15 • Phase III Randomized Trial | N = 1,012 | 96/100 | PMID 40326221 ↗ |
| New Insights on Relugolix combination therapy in European women with symptomatic uterine: What a 388-Participant Study Found In European women with UF and HMB, once-daily relugolix-CT vs. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology • 2023-08-17 • Phase III Randomized Trial | N = 388 | 93/100 | PMID 37634528 ↗ |
| What the Latest Evidence Really Says About Effects of sildenafil citrate on intrauterine growth Sildenafil citrate increases birth weight and prolonged pregnancies but did not affect stillbirth rate, neonatal death, and NICU admission. BMC pregnancy and childbirth • 2023-06-02 • Meta-Analysis | Multi-cohort | 92/100 | PMID 37268873 ↗ |
| Can This Approach Help? Inside the Latest Research on Once Daily Oral Relugolix Combination Therapy Versus Placebo in Patients With The author describes the results of a study to examine the effect of three treatment regimens on pain associated with endometriosis. Journal of obstetric, gynecologic, and neonatal nursing : JOGNN • 2024-11-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39395815 ↗ |
| Can This Approach Help? Inside the Latest Research on Effects of magnesium supplementation on abnormal uterine bleeding, hair loss, Magnesium supplementation in women with PCOS had a significant positive effect on improving total quality of life. Reproductive biology and endocrinology : RB&E • 2022-08-02 • Randomized Controlled Trial | N = 64 | 88/100 | PMID 35918728 ↗ |
Uterine prolapse Patient Community & “People Like Me” Threads
Filter Uterine prolapse community threads and patient logs by age, biological sex, dosage, and treatment duration.